


AMENDMENTS TO THE CLAIMS: This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) An oligomeric compound having the formula:




wherein:

each Bx is, independently, a heterocyclic base moiety;

T₂ is hydroxyl, a protected hydroxyl, an oligonucleotide or an oligonucleoside;

T₁ is a modified phosphate having the formula:



wherein

one of Q₁ and Q₂ is S and the other of Q₁ and Q₂ is O;

[[Q₃]] Q is OH or CH₃ when Q₂ is S and CH₃ when Q₂ is O;

R₁, R₃ and each R₂ are, independently, hydrogen, hydroxyl, a sugar substituent group, group or a protected sugar substituent group or said modified phosphate group;

each X₁ and X₂ is, independently, O or S wherein at least one X₁ is S; and

n is from 3 to 48.

2-3. (canceled)

4. (currently amended) The oligomeric compound of claim 1 wherein $[[Q_3]]$ Q is CH₃.

5-10. (canceled)

11. (original) The oligomeric compound of claim 1 wherein R₁, R₃ and each R₂ is hydrogen.

12. (original) The oligomeric compound of claim 1 wherein R₁, R₃ and each R₂ is hydroxyl.

13. (previously presented) The oligomeric compound of claim 1 wherein R₁, R₃ and each R₂ are, independently, hydrogen, hydroxyl, a sugar substituent group or a protected sugar substituent group.

14. (original) The oligomeric compound of claim 1 wherein at least one of R₁, R₂ or R₃ is an optionally protected sugar substituent group.

15. (original) The oligomeric compound of claim 1 wherein each X₂ is S.

16. (original) The oligomeric compound of claim 1 wherein each heterocyclic base moiety is, independently, adenine, cytosine, 5-methylcytosine, thymine, uracil, guanine or 2-aminoadenine.

17. (original) The oligomeric compound of claim 1 wherein n is from about 8 to about 30.

18. (original) The oligomeric compound of claim 1 wherein n is from about 15 to 25.

19. (withdrawn) A method of treating an organism having a disease characterized by the undesired production of a protein comprising contacting the organism with an oligomeric compound of claim 1.

20. (previously presented) A composition comprising:
a pharmaceutically effective amount of an oligomeric compound of claim 1; and
a pharmaceutically acceptable diluent or carrier.

21. (withdrawn) A method of modifying *in vitro* a nucleic acid, comprising contacting a test solution containing RNase H and said nucleic acid with an oligomeric compound of claim 1.

22. (withdrawn) A method of concurrently enhancing hybridization and RNase H activation in a organism comprising contacting the organism with an oligomeric compound of claim 1.

23. (withdrawn) A method comprising contacting a cell with an oligomeric compound of claim 1.

24-41. (canceled)